Imatinib mesylate--a new oral targeted therapy.
暂无分享,去创建一个
[1] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[2] Sigrid Stroobants,et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.
[3] B. Druker,et al. Chronic myeloid leukemia: current treatment options. , 2001, Blood.
[4] H. Kantarjian,et al. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. , 2001, Blood.
[5] C. Prins,et al. Acute Generalized Exanthematous Pustulosis Associated with STI571 in a Patient with Chronic Myeloid Leukemia , 2001, Dermatology.
[6] C. Sawyers. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. , 2001, Seminars in hematology.
[7] M. Talpaz. Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. , 2001, Seminars in hematology.
[8] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[9] C. Verfaillie,et al. Novel therapies for chronic myelogenous leukemia. , 2001, Experimental hematology.
[10] M. Pierotti,et al. Growth‐inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement , 2001, International journal of cancer.
[11] J. Melo,et al. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[12] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[13] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[14] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[15] Dr Tessa L. Holyoake. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory , 2001, British journal of haematology.
[16] F. Rossi,et al. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease , 2001, British journal of haematology.
[17] G. Daley,et al. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. , 2001, Blood.
[18] P. Vigneri,et al. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase , 2001, Nature Medicine.
[19] Stephanie J. Lee. CHRONIC MYELOGENOUS LEUKAEMIA , 2000, British journal of haematology.
[20] J. Melo,et al. The molecular biology of chronic myeloid leukemia. , 2000, Blood.
[21] K. Kolibaba,et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. , 2000, Blood.
[22] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[23] P. Black,et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. , 2000, Cancer research.
[24] C. L. Perkins,et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. , 2000, Blood.
[25] B. Druker,et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.
[26] S. Honsawek,et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] J. Melo,et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.
[28] R. Salgia,et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.
[29] B. Vanderhyden,et al. Lack of expression of c‐KIT in ovarian cancers is associated with poor prognosis , 2000, International journal of cancer.
[30] C. Pui,et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2000, The New England journal of medicine.
[31] J. Melo,et al. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. , 2000, Cancer research.
[32] J. Goldman. Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia , 2000, The Lancet.
[33] M. Varella‐Garcia,et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.
[34] S. Sacchi,et al. Chronic myelogenous leukemia in nonlymphoid blastic phase , 1999, Cancer.
[35] W. Siegert,et al. Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure , 1999 .
[36] J. Lasota,et al. Gastrointestinal stromal tumors: recent advances in understanding of their biology. , 1999, Human pathology.
[37] L. Sobin,et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. , 1999, The American journal of surgical pathology.
[38] Z. Estrov,et al. The biology of chronic myeloid leukemia. , 1999, The New England journal of medicine.
[39] C. Sawyers. Chronic myeloid leukemia. , 1999, The New England journal of medicine.
[40] C. Sawyers,et al. Tyrosine kinase inhibitors in chronic myeloid leukemia. , 1999, The cancer journal from Scientific American.
[41] E. Buchdunger,et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. , 1999, Journal of the National Cancer Institute.
[42] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.
[43] K. Sullivan,et al. Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase , 1998 .
[44] Z. Estrov,et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] D. Arber,et al. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. , 1998, Human pathology.
[46] R. Bhatia,et al. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. , 1998, Blood.
[47] C Anasetti,et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.
[48] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[49] M. Carroll,et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.
[50] K. Kolibaba,et al. Protein tyrosine kinases and cancer. , 1997, Biochimica et biophysica acta.
[51] C. Sawyers,et al. Signal transduction by wild-type and leukemogenic Abl proteins. , 1997, Biochimica et biophysica acta.
[52] J. Melo,et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.
[53] G. Gahrton,et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation , 1997, Bone Marrow Transplantation.
[54] C Chastang,et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. , 1997, The New England journal of medicine.
[55] C. Anasetti,et al. 9 Allografting for chronic myeloid leukaemia , 1997 .
[56] J P Klein,et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] D. Baltimore,et al. Identification of the Abl- and rasGAP-Associated 62 kDa Protein as a Docking Protein, Dok , 1997, Cell.
[58] R. Kobayashi,et al. p62 dok : A Constitutively Tyrosine-Phosphorylated, GAP-Associated Protein in Chronic Myelogenous Leukemia Progenitor Cells , 1997, Cell.
[59] J. Goldman,et al. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period , 1997, British journal of haematology.
[60] H. Antoniades,et al. Expression of platelet‐derived growth factor (PDGF)‐A, PDGF‐B and the PDGF‐alpha receptor, but not the PDGF‐beta receptor, in human malignant melanoma in vivo , 1996, The British journal of dermatology.
[61] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[62] V. Kaartinen,et al. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. , 1995, Blood.
[63] D. Cortez,et al. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis , 1995, Molecular and cellular biology.
[64] R Ohno,et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. , 1995, Blood.
[65] S. Richards,et al. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.
[66] A. Elmaagacli,et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. , 1995, Blood.
[67] E. Copelan,et al. The biology and treatment of acute lymphoblastic leukemia in adults. , 1995, Blood.
[68] H. Kantarjian,et al. Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- Therapy , 1995, Annals of Internal Medicine.
[69] R. Seeger,et al. Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group , 1994 .
[70] B. Zehnbauer,et al. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. , 1994, Blood.
[71] Sante Tura,et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. , 1994, The New England journal of medicine.
[72] T Pawson,et al. Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway. , 1994, The EMBO journal.
[73] C. Bloomfield,et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and leukemia group B study 8583 , 1993 .
[74] Nanxin Li,et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein , 1993, Cell.
[75] M. Horowitz,et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase , 1993 .
[76] G. Burgess,et al. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. , 1993, Blood.
[77] H. Heimpel,et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. , 1993, Blood.
[78] S. Seeber,et al. Impact of interferon alpha‐induced cytogenetic improvement on survival in chronic myelogenous leukaemia , 1993, British journal of haematology.
[79] C. Bloomfield,et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). , 1992, Blood.
[80] M. Vekemans,et al. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. , 1992, Blood.
[81] G. Daley,et al. Blast crisis in a murine model of chronic myelogenous leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[82] E. Estey,et al. Intensive chemotherapy induction followed by interferon‐alpha maintenance in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia , 1991, Cancer.
[83] J. Goldman,et al. Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. , 1991, Blood.
[84] O. Witte,et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.
[85] G. Daley,et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.
[86] A. Levitzki,et al. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors , 1988, Science.
[87] B. Clarkson,et al. Discordant maturation as the primary biological defect in chronic myelogenous leukemia. , 1988, Cancer research.
[88] H. Kantarjian,et al. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high‐dose decadron , 1987, Cancer.
[89] M. Greaves,et al. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia , 1987, Nature.
[90] H. Kantarjian,et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. , 1986, The New England journal of medicine.
[91] E. Canaani,et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.
[92] J. Stephenson,et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.
[93] J. Stephenson,et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia , 1983, Nature.
[94] J. Stephenson,et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia , 1983, Nature.
[95] J. Gutterman,et al. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. , 1983, Blood.
[96] R. Hamman,et al. Busulfan versus hydroxyurea in long‐term therapy of chronic myelogenous leukemia , 1982, Cancer.
[97] D. Catovsky,et al. MARROW TRANSPLANTATION FOR PATIENTS IN THE CHRONIC PHASE OF CHRONIC GRANULOCYTIC LEUKAEMIA , 1982, The Lancet.
[98] P. Neiman,et al. TREATMENT OF CHRONIC GRANULOCYTIC LEUKAEMIA IN CHRONIC PHASE BY ALLOGENEIC MARROW TRANSPLANTATION , 1982, The Lancet.
[99] T. Lister,et al. Relation of “lymphoid” phenotype and response to chemotherapy incorporating vincristine‐prednisolone in the acute phase of Ph1 positive leukemia , 1979, Cancer.
[100] J. Rowley. A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.
[101] C. Heldin,et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. , 2001, Cancer research.
[102] J. Griffin,et al. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. , 2000, Blood.
[103] M. Zucchetti,et al. Role of (cid:1) 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI571 , 2000 .
[104] B. Druker,et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.
[105] L. Sobin,et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. , 1999, The American journal of surgical pathology.
[106] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.
[107] R. Salgia,et al. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. , 1994, Experimental hematology.
[108] J. Goldman,et al. Chronic myelogenous leukemia. , 1985, Critical reviews in oncology/hematology.
[109] P. Nowell,et al. A minute chromosome in human chronic granulocytic leukemia , 1960 .